Zacks Research Weighs in on Allogene Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLOFree Report) – Zacks Research issued their FY2026 earnings per share estimates for Allogene Therapeutics in a research report issued on Thursday, March 28th. Zacks Research analyst S. Ganoria expects that the company will post earnings per share of ($1.93) for the year. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.72) per share.

Other equities research analysts have also recently issued reports about the company. Guggenheim cut Allogene Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, January 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 15th. JPMorgan Chase & Co. cut their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 27th. Citigroup assumed coverage on Allogene Therapeutics in a report on Friday, December 8th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, JMP Securities reiterated a “market perform” rating on shares of Allogene Therapeutics in a report on Friday, January 5th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $13.17.

Read Our Latest Research Report on ALLO

Allogene Therapeutics Stock Performance

ALLO stock opened at $4.47 on Friday. The stock has a market capitalization of $755.83 million, a price-to-earnings ratio of -2.14 and a beta of 0.81. Allogene Therapeutics has a 1 year low of $2.23 and a 1 year high of $6.89. The stock’s fifty day moving average is $4.44 and its two-hundred day moving average is $3.51.

Institutional Trading of Allogene Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ALLO. Goldman Sachs Group Inc. boosted its holdings in Allogene Therapeutics by 137.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,337,214 shares of the company’s stock valued at $10,712,000 after acquiring an additional 1,929,258 shares during the last quarter. American International Group Inc. boosted its holdings in Allogene Therapeutics by 14.5% in the fourth quarter. American International Group Inc. now owns 46,967 shares of the company’s stock valued at $151,000 after acquiring an additional 5,955 shares during the last quarter. Virtus ETF Advisers LLC boosted its holdings in Allogene Therapeutics by 72.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 34,163 shares of the company’s stock valued at $110,000 after acquiring an additional 14,328 shares during the last quarter. Voya Investment Management LLC boosted its holdings in Allogene Therapeutics by 14.5% during the fourth quarter. Voya Investment Management LLC now owns 38,347 shares of the company’s stock worth $123,000 after buying an additional 4,851 shares during the last quarter. Finally, Brevan Howard Capital Management LP boosted its holdings in Allogene Therapeutics by 433.9% during the fourth quarter. Brevan Howard Capital Management LP now owns 98,120 shares of the company’s stock worth $315,000 after buying an additional 79,743 shares during the last quarter. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Company Profile

(Get Free Report)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.

Featured Stories

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.